Evofem Biosciences Inc EVFM

NAS: EVFM | ISIN: US30048L1044   14/11/2024
0,010 USD (-16,67%)
(-16,67%)   14/11/2024

1 juni 2023 · Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023 · Persbericht

17 mei 2023 · Evofem Biosciences Announces 1-for-125 Reverse Stock Split · Persbericht

12 april 2023 · Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required · Persbericht

21 maart 2023 · Evofem Biosciences Announces Cost Reduction Measures · Persbericht

9 maart 2023 · Evofem Biosciences Appoints Interim Chief Financial Officer · Persbericht

28 februari 2023 · Evofem's Phexxi Contraceptive Gel Added to SimpleHealth Product Offering · Persbericht

27 februari 2023 · Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi · Persbericht

23 februari 2023 · Evofem Biosciences to Explore Strategic Alternatives to Maximize Shareholder Value · Persbericht

10 januari 2023 · Costco Adds Phexxi® to Member Prescription Program · Persbericht

10 januari 2023 · Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women · Persbericht

9 januari 2023 · Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women · Persbericht

11 augustus 2022 · Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022 · Persbericht

4 augustus 2022 · Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance · Persbericht

3 augustus 2022 · Evofem Biosciences Strengthens Board of Directors · Persbericht

1 augustus 2022 · Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women · Persbericht

29 juli 2022 · Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals · Persbericht

28 juli 2022 · Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022 · Persbericht

26 juli 2022 · Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition · Persbericht

25 juli 2022 · Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling · Persbericht

22 juli 2022 · Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act · Persbericht

Mijn selecties